Drugs for Bladder Cancer (Urothelial Carcinoma)

Janssen CarePath Savings Program

With this program, eligible, privately insured patients will pay just $5 per month for Balversa, with an annual benefit up to $25,000. The savings may apply toward copay, coinsurance, or deductible, depending on the patient’s health insurance plan.

Johnson & Johnson Patient Assistance Foundation

This program provides Balversa free of charge to patients who meet certain financial criteria and who are uninsured, underinsured, or enrolled in Medicare Part D.

CoverOne Co-Pay Assistance Program

Through this program, patients with private insurance will be responsible for a $0 copay for Bavencio at participating medical facilities and pharmacies, and may be eligible for copay assistance up to a maximum of $30,000 annually.

CoverOne Patient Assistance Program

This program provides Bavencio at no charge for patients who meet certain income, insurance, and residency eligibility criteria.

Imfinzi Co-pay Savings Program

Patients with private insurance will pay $0 per infusion of Imfinzi; this program pays the remaining out-of-pocket costs up to a maximum of $26,000 annually, with a program maximum of $100 per infusion assistance. Residents of Massachusetts, Michigan, Minnesota, and Rhode Island are not eligible for this assistance.

AZ&Me Prescription Savings Program

This prescription savings program offers free, mail-based medication to qualifying patients who have no insurance, those who have Medicare Part D coverage, and some patients with Medicare Part B coverage. General eligibility requirements include limited household income and/or a life-changing event in the past year that affected the patient’s finances. Patients with Medicare Part D coverage must spend 3% of their total household income on prescription medicines through a Medicare Part D prescription plan during the current calendar year, and must be unable to enroll in Medicare Limited Income Subsidy.

Patients with Medicare Part B coverage should call 800-292-6363 for program requirements. Once accepted into the program, patients will be enrolled for 1 year (with the option to re-enroll) and a supply of the medication (up to 90 days) will be sent directly to the patient. Refills need to be requested by the doctor or the patient.

UroGen Support Copay Program

Eligible patients who have commercial or private health insurance will pay as little as $50 per dose of Jelmyto, with a maximum benefit of $4,000 per dose, and a maximum total benefit of up to $13,000 per year. To qualify for this program, patients must be enrolled in the UroGen Support Program.

UroGen Support Patient Assistance Program

Patients with no health insurance who are prescribed Jelmyto for an FDA-approved indication and have an adjusted gross income of up to 400% of the federal poverty level, may receive Jelmyto for free.

Merck Co-pay Assistance Program

Privately insured patients will pay the first $25 of their copay per Keytruda infusion. The maximum benefit per calendar year is $25,000.

Merck Patient Assistance Program

Patients without insurance or prescription coverage may be eligible to receive Keytruda at no cost. Eligible patients must have a household income of $63,800 or less for individuals, $86,200 or less for a couple, or $131,000 or less for a family of 4. Patients with insurance, including Medicare Part D, who still have trouble paying for their medicines may request that an exception be made, provided their household income is not above a set limit.

BMS Oncology Co-Pay Assistance Program

This program provides financial assistance with out-of-pocket deductibles, copay, or coinsurance costs for eligible patients with private insurance who have been prescribed Opdivo. Patients pay a $25 copay, while BMS covers the remaining amount, up to $25,000 annually per medication.

Bristol Myers Squibb Patient Assistance Foundation

Patients who don’t have public or private insurance that helps to pay for Opdivo may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $38,280 for an individual or $51,720 for a family of 2.

Padcev Copay Assistance Program

Eligible patients who have private or commercial insurance will pay $5 per dose of Padcev, up to a maximum of $25,000 annual benefit. Patients will be enrolled in this program for 12 months. This program has no income requirements.

Padcev Patient Assistance Program

Eligible patients who have no insurance or have no insurance coverage for Padcev and meet the program requirements will receive Padcev free of charge.

Genentech Oncology Co-pay Assistance Program

Eligible patients with private insurance will pay just a $5 copay per prescription or infusion of Tecentriq, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Tecentriq free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria.